An expanded panel of biomarkers
The expanded panel includes bTMB, MSI status, expanded HRR gene set, and full coverage of NTRK fusions.3,5-7
| Guardant360 Panel3,5,7 | Guardant360 Panel3,5,7 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKT1 | FGFR2 | NOTCH1 | ||||||||||
| ALK | FGFR3 | NPM1 | ||||||||||
| APC | GATA3 | NRAS | ||||||||||
| AR | GNA11 | NTRK1 | ||||||||||
| ARAF | GNAQ | NTRK2 | ||||||||||
| ARID1A | GNAS | NTRK3 | ||||||||||
| ATM | HNF1A | PALB2 | ||||||||||
| BRAF | HRAS | PDGFRA | ||||||||||
| BRCA1 | IDH1 | PIK3CA | ||||||||||
| BRCA2 | IDH2 | PMS2 | ||||||||||
| CCND1 | JAK2 | PTEN | ||||||||||
| CCND2 | JAK3 | PTPN11 | ||||||||||
| CCNE1 | KEAP1 | RAD51D | ||||||||||
| CDH1 | KIT | RAF1 | ||||||||||
| CDK12 | KRAS | RB1 | ||||||||||
| CDK4 | MAP2K1 | RET | ||||||||||
| CDK6 | MAP2K2 | RHEB | ||||||||||
| CDKN2A | MAPK1 | RHOA | ||||||||||
| CHEK2 | MAPK3 | RIT1 | ||||||||||
| CTNNB1 | MET | ROS1 | ||||||||||
| DDR2 | MLH1 | SMAD4 | ||||||||||
| EGFR | MPL | SMO | ||||||||||
| ERBB2 | MSH2 | STK11 | ||||||||||
| ESR1 | MSH6 | TERT | ||||||||||
| EZH2 | MTOR | TP53 | ||||||||||
| FANCA | MYC | TSC1 | ||||||||||
| FBXW7 | NF1 | VHL | ||||||||||
| FGFR1 | NFE2L2 | |||||||||||
| AKT1 | CCND1 | DDR2 | GATA3 | KEAP1 | MSH2 | NTRK2 | RB1 | TP53 | ||||
| ALK | CCND2 | EGFR | GNA11 | KIT | MSH6 | NTRK3 | RET | TSC1 | ||||
| APC | CCNE1 | ERBB2 | GNAQ | KRAS | MTOR | PALB2 | RHEB | VHL | ||||
| AR | CDH1 | ESR1 | GNAS | MAP2K1 | MYC | PDGFRA | RHOA | |||||
| ARAF | CDK12 | EZH2 | HNF1A | MAP2K2 | NF1 | PIK3CA | RIT1 | |||||
| ARID1A | CDK4 | FANCA | HRAS | MAPK1 | NFE2L2 | PMS2 | ROS1 | |||||
| ATM | CDK6 | FBXW7 | IDH1 | MAPK3 | NOTCH1 | PTEN | SMAD4 | |||||
| BRAF | CDKN2A | FGFR1 | IDH2 | MET | NPM1 | PTPN11 | SMO | |||||
| BRCA1 | CHEK2 | FGFR2 | JAK2 | MLH1 | NRAS | RAD51D | STK11 | |||||
| BRCA2 | CTNNB1 | FGFR3 | JAK3 | MPL | NTRK1 | RAF1 | TERT | |||||
Liquid CGP testing provides guideline-complete genotyping more often than tissue-only testing.1
Resulted in guideline-complete genotyping in 95% of patients, compared with 18% in patients with tissue genotyping alone (n=268 for ctDNA arm; n=51 for tissue arm).1
Get results faster so patients can start treatment sooner.
vs
Patients testing with Guardant360® started targeted therapy
approximately 18 days following the initiation of testing, compared with 31 days for those who underwent tissue biopsies. All patients responded to targeted therapy similarly regardless of biopsy type.2
Treatment response results are comparable between liquid CGP testing and tissue testing.8
PFS rates in patients receiving targeted therapy,
based on results from tissue vs ctDNA testing8
based on results from tissue vs ctDNA testing8
NON-SMALL CELL LUNG CANCER (NSCLC) DATA
Identify more actionable biomarkers to inform treatment selection.4
Guardant360® in combination with
tissue biopsy identified nearly 2X more patients with targeted biomarkers
versus tissue biopsy alone.4
NSCLC patients with targeted mutations detected by testing modality9
| Tissue alone | 47 |
| Tissue + Guardant360 | 82 |
| Tissue alone | 47 |
| Tissue + Guardant360 | 82 |
In rescue cases of QNS, 44% of tissue biopsy patients were unable to get results from tissue alone.9
Comprehensive support across the cancer continuum.
Guardant Portal
Easy access to test ordering and management with simple order forms.
Clear, concise reports, including therapy and clinical trial options.
Easy and Convenient Sample Collection
A mobile phlebotomy service makes sample collection as easy and convenient as possible by meeting patients at their location.
References: 1. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691-4700. doi:10.1158/1078-0432.CCR-19-0624 2. Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(1):72-81. doi:10.1016/j.cllc.2021.10.001 3. Guardant360® Assay Specifications. Guardant Health, Inc. Redwood City, CA. 4. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 5. National Institutes of Health. Guardant360. National Library of Medicine; Bethesda, MD. Updated August 12, 2021. Accessed June 29, 2023. https://www.ncbi.nlm.nih.gov/gtr/tests/527948. 6. Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2:1-13. doi:10.1200/PO.17.00286 7. Guardant360® Gene Pocket Guide. Guardant Health, Inc. Redwood City, CA. 8. Palmero R, Taus A, Viteri S, et al. Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:93-102. doi:10.1200/PO.20.00241 9. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic nonsmall cell lung cancer. JAMA Oncol. 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305 10. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021.